By Kevin Jagernauth | The Playlist July 9, 2014 at 12:38PM
"That thing has been in development for over three years. Interesting how the week I have a film coming out someone decides it's a good idea to promote this. Not sure what they hope to gain," "Boyhood" director Richard Linklater told Indiewire about the brewing remake of "The Incredible Mr. Limpet," one that he also recently said "wasn't happening." So take this next bit of info with a grain or three of salt.
According to The Wrap, Jon Hamm, Danny McBride, Sarah Silverman, Kevin Hart, Josh Gad, Keegan Michael Key and Jordan Peele are all in talks for roles for 'Limpet,' with Zach Galifianakis still attached to star. The trade says that if everything goes according to plan production might start this fall, but it would seem that someone needs to tell Linklater this is happening first.
Meanwhile, another project that looks to have fallen by the wayside is "Larry's Kidney." First announced this past spring, the project would've reteamed Will Ferrell and Zach Galifianakis, in the adaptation of the memoir by Daniel Asa Rose, about a man who travels with his cousin and mail-order bride to China in order to get a life-saving kidney transplant.
"That project's not happening. The financing kind of went away," Linklater told IW. "...that's the thing with those announcements. You never know. You never know the reason why it gets announced, but it's usually someone on the financing or sales side trying to influence something. I don't know why. The financing we thought we had disappeared. We might get it made sometime, but I have hopes for another thing."
Okay, enough about the stuff Linklater probably won't do and let's get back to the movie he does have coming out—"Boyhood." The director stopped by Film4 to record a ten minute interview and discussion about his epic drama, so click below to see what he has to say and be sure to buy a ticket when it opens this weekend in limited release. And after that, check out some Alamo Drafthouse PSAs by the director as well via Indiewire.